Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP’s Takaichi Elected as Japan’s First Female Prime Minister
Sanae Takaichi, president of the ruling Liberal Democratic Party (LDP), was elected as Japan’s first female prime minister in a parliamentary vote on October 21. The new Takaichi Cabinet was launched under a coalition with the Japan Innovation Party (Nippon…
To read the full story
Related Article
- New Health Minister Pledges to Strengthen Japan’s Drug Discovery Capabilities
October 23, 2025
- JPMA Chief Hails Takaichi’s Election as PM, Calls for Stronger Innovation Ecosystem
October 22, 2025
- Takaichi Faces Tough Balancing Act on Healthcare, Nursing Reform
October 22, 2025
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
- Komeito’s Exit from Ruling Coalition Casts Uncertainty over Japan’s Drug Policy
October 15, 2025
- Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
- Takaichi Vows Hospital Support via Extra Budget; MHLW Sees Boost for Funding Requests
October 7, 2025
- LDP Leadership Race Underway, Healthcare-Savvy Lawmakers Among Endorsers
September 24, 2025
- Takaichi Highlights Drug Discovery as Crucial Growth Field in LDP Race
September 22, 2025
- Hayashi Stresses Drug Discovery as Key Growth Field in LDP Race
September 19, 2025
- Motegi Calls for Lowering Generic Prices by Consolidation: LDP Race
September 11, 2025
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…